Effects of statin use on total oxidant and antoxidant capacity and ceruloplasmin activity

Buyukhatipoglu, Hakan; Sezen, Yusuf; Yildiz, Ali; Guntekin, Unal; Bas, Memduh; Polat, Mustafa; Demirbag, Recep; Taskin, Abdullah; Celik, Hakim; Aksoy, Nurten
October 2010
Clinical & Investigative Medicine;Oct2010, Vol. 33 Issue 5, pE313
Academic Journal
Purpose: Oxidative damage plays an important role in atherosclerosis development. Statin drugs have anti-oxidant properties, but the clinical value of their antioxidant properties remains unclear. In this study, our aims were: (1) to assess the anti-oxidant effects of statins in patients with coronary artery disease (CAD) using a newly developed valid measure of total oxidant and anti-oxidant capacity; and (2) to identify whether statins influence ceruloplamin levels. Methods: Within a cross sectional study, 67 dyslipidemic CAD patients on atorvastatin for at least three months were compared with 69 age- and gender matched CAD patients not using atorvastatin. All patients were either newlydiagnosed with or already had established CAD. Patients and controls were selected from among patients who had undergone coronary angiography for a variety of reasons. Immediately prior to angiography, plasma total oxidant and antioxidant capacity and ceruloplasmin (Cp) levels weremeasured by means of a relatively new and highly-reliable method. Results: Total oxidant capacity levels were significantlylower and total antioxidant capacity significantly higher in those on atorvastatin; serum seruloplasmin levels also were significanly increased in the atorvastatin groups (all p < 0.05). On multivariate analysis, atorvastatin use was a significant determinant of Cp increase, independent of any antioxidant effect. Conclusions: This study clearly demonstrates increased anti-oxidant capacity and decreased oxidative stress with statin use. Atorvastatin use may also increase Cp levels although this effect appears to be independent of its antioxidant effects.


Related Articles

  • Smoking, Oxidative Stress and Cardiovascular Diseases-Do Anti-Oxidative Therapies Fail? Bernhard, D.; Wang, X. L. // Current Medicinal Chemistry;2007, Vol. 14 Issue 16, p1703 

    Oxidative reactions caused by cigarette smoke (CS) chemicals have been shown to initiate crucial events in atherogenesis. However, physicians and scientists are confronted with the paradoxical situation that an antioxidative treatment of smokers improves acute smoking effects but hardly has any...

  • Statins: 3-Hydroxy-3-methylglutaryl-CoA (HMG-CoA) Reductase Inhibitors Demonstrate Anti-Atherosclerotic Character due to Their Antioxidant Capacity. Puttananjaiah, Mohan-Kumari H.; Dhale, Mohan Appasaheb; Gaonkar, Vaishali; Keni, Shradha // Applied Biochemistry & Biotechnology;Jan2011, Vol. 163 Issue 2, p215 

    herosclerosis is a chronic inflammatory disease of multiple etiologies. It is associated with the accumulation of oxidized lipids in arterial lesions leading to coronary heart disease. 3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (commonly known as statins) are widely...

  • Evaluation of cholesterol-lowering and antioxidant properties of sugar cane policosanols in hamsters and humans. Kassis, Amira N. // Applied Physiology, Nutrition & Metabolism;Jun2008, Vol. 33 Issue 3, p540 

    Atherosclerosis prevention is now a main focus of the scientific community and pharmaceutical industry. Sugar cane policosanols (SCPs) have gained increasing popularity over the last decade as a result of numerous studies conducted in Cuba that consider SCPs as a natural alternative to statin...

  • Targeting residual cardiovascular risk: risk high-density lipoprotein cholesterol levels. Hausenloy, D. J.; Yellon, D. M. // Postgraduate Medical Journal;Nov2008, Vol. 84 Issue 997, p590 

    The last 20 years have witnessed dramatic reductions in cardiovascular risk using 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors ("statins") to lower levels of low-density lipoprotein cholesterol (LDL-C). Using this approach one can achieve a reduction in the risk of major...

  • Higher HDL Cholesterol in Statin Therapy, Key to Slowing Atherosclerosis? Elliott, William T. // Internal Medicine Alert;3/15/2007, Vol. 29 Issue 5, Special section p1 

    The article focuses on the results of a study on the relation of aggressive statin therapy to slowed progression and regression of atherosclerosis.

  • ASHP Therapeutic Position Statement on the Use of Statins in the Prevention of Atherosclerotic Vascular Disease in Adults.  // American Journal of Health-System Pharmacy;3/15/2003, Vol. 60 Issue 6, p593 

    Presents statement by the American Society of Health-System Pharmacists (ASHP) on the use of statins in the prevention of atherosclerotic vascular disease (ASVD) in adults. Pathophysiology of atherosclerosis and lipid metabolism; Pharmocology of statins; Guidelines for the evaluation and...

  • Update on statin-mediated anti-inflammatory activities in atherosclerosis. Montecucco, Fabrizio; Mach, François // Seminars in Immunopathology;2009, Vol. 31 Issue 1, p127 

    Anti-inflammatory activities of statins in atherosclerosis have been well documented by both basic research and clinical studies. Statins have been introduced in the 1980s as 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors to block cholesterol synthesis and lower cholesterol serum...

  • EP2300 Compounds: Focusing on the Antiatherosclerotic Properties of Squalene Synthase Inhibitors. Tavridou, A.; Manolopoulos, V. G. // Current Pharmaceutical Design;9/21/2009, Vol. 15 Issue 27, p3167 

    Although treatment with statins significantly reduces adverse cardiovascular outcomes, several studies have shown that cardiovascular events continue to occur in two thirds of all patients. A logical pharmacologic approach to further reduce cardiovascular disease mortality should be focused on...

  • Association of Nitrotyrosine Levels With Cardiovascular Disease and Modulation by Statin Therapy. Shishehbor, Mehdi H.; Aviles, Ronnier J.; Brennan, Marie-Luise; Fu, Xiaoming; Goormastic, Marlene; Pearce, Gregory L.; Gokce, Noyan; Keaney, Jr, John F.; Penn, Marc S.; Sprecher, Dennis L.; Vita, Joseph A.; Hazen, Stanley L. // JAMA: Journal of the American Medical Association;4/2/2003, Vol. 289 Issue 13, p1675 

    Context: Formation of nitric oxide–derived oxidants may serve as a mechanism linking inflammation to development of atherosclerosis. Nitrotyrosine, a specific marker for protein modification by nitric oxide–derived oxidants, is enriched in human atherosclerotic lesions and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics